Vertex Pharmaceuticals is marching toward the launch of exagamglogene autotemcel (exa-cel), its potential one-time treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) – with a lot of confidence, per its full-year 2022 presentation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,